Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Glioblastoma
- Malignant Solid Neoplasm
- Design
- Observational Model: Case-OnlyTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
PRIMARY OBJECTIVES: I. Assessment of cell yield and percentage of viable cells upon tissue receipt at the cell processing facility. II. Obtain discarded tumor tissue from surgical resections for further studies to aid in development of future therapies for glioblastoma (GBM) and other solid tumors. ...
PRIMARY OBJECTIVES: I. Assessment of cell yield and percentage of viable cells upon tissue receipt at the cell processing facility. II. Obtain discarded tumor tissue from surgical resections for further studies to aid in development of future therapies for glioblastoma (GBM) and other solid tumors. SECONDARY OBJECTIVE: I. Assessment of cell yield and percentage of viable cells from other solid tumor cells shipped to the cell processing facility. EXPLORATORY OBJECTIVE: I. An additional line of inquiry will be devoted to scientific exploration of the product's immunogenicity looking at important variables in the course of manufacture. OUTLINE: Patients undergo collection of tissue sample during surgery. Patients also undergo collection of blood sample.
Tracking Information
- NCT #
- NCT04822688
- Collaborators
- Not Provided
- Investigators
- Not Provided